Abstract
Introduction Noncommunicable diseases are the leading causes of premature mortality worldwide. Both genetic predispositions and environmental exposure affect disease risk. While biobanks have increased understanding of genetic predictors of these diseases, environmental influences are expected to have a greater impact on disease development. Individuals also create their own environments and lifestyles based on genetically regulated preferences, leading to gene– environment interactions that require large datasets to study. Biobanks may lack sufficient lifestyle and environmental data, which limits their use. We present a protocol for a biobank-recall study (BioRecall) to collect data on lifestyle and environmental exposure and combine these findings with genotypes, biological samples and clinical outcomes.
Methods and analysis All previously genotyped donors of the Central Finland Biobank diagnosed with type 2 diabetes and consenting to recalls will be invited to the pilot study. The preliminary feasibility assessment reveals that there are 1,386 suitable candidates. Participants will complete an electronic questionnaire on a secured online platform. The questionnaire includes validated questions on lifestyles, anthropometrics, weight loss history, health, symptoms, work characteristics, emotional states and residential environments. Postcode information will facilitate the addition of spatial environmental data. Genotype and related clinical data will be provided in the study in accordance with the Finnish Biobank Act and combined with questionnaire data.
Ethics and open data The Human Sciences Ethics Committee of the University of Jyväskylä delivered a favourable statement regarding the study protocol (1671/13.00.04.00/2023). Central Finland Biobank approved the research plan (no: BB24-0333-A01). The data collected will be returned to the Central Finland Biobank for research purposes with the participants’ consent. Permission for data usage can then be applied through standard protocols of the Fingenious® service (www.fingenious.fi). If successful, the study will be expanded to other donors and Finnish biobanks.
Strengths and limitations
Low-cost, scalable approach: A fully electronic consent and data collection concept with the potential to expand data collection to all genotyped Finnish individuals with biobank consent will be employed.
Extensive dataset: The study will form an extensive dataset covering lifestyle and environmental exposure to investigate the prevention of non-communicable diseases. In the pilot phase, the sample size is limited, and only one biobank is included.
Automated feedback: As the survey progresses, respondents receive feedback on their own answers, primarily in relation to national lifestyle recommendations. Automated instant feedback may improve response rates. This feature could facilitate low-cost health promotion interventions.
Innovative physical activity assessment: Novel questions on strength training and balance that complement WHO’s Global Physical Activity Questionnaire (GPAQ) will enable the assessment of compliance with current physical activity recommendations.
Lack of wearable data: The concept does not include data collection using wearables.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is supported by the JYU.Well strategic funding received from the University of Jyvaskyla (to ES) and the research infrastructure funding received from the Research Council of Finland (grant number: 358894 to ES) as part of the BBMRI.fi consortium. ES is supported by the Research Council of Finland (grant numbers: 341750, 346509, and 361981), Juho Vainio Foundation and Paivikki and Sakari Sohlberg Foundation. SR and TF are supported by Juho Vainio Foundation. MR is supported by the Research Council of Finland (grant number: 330185). KA is partially supported by the European Regional Development Fund through the Regional Council of Northern Savo (No. A80407) for the development of FOODNUTRI infrastructure and by the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI), funded by the EU4Health Programme (Grant Agreement No. 101126953).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Sciences Ethics Committee of the University of Jyvaskyla has delivered a favourable statement about the study protocol (1671/13.00.04.00/2023). Central Finland Biobank approved the research plan (no: BB24-0333-A01).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised for language errors and fluency.
Data Availability
The Finnish biobank data can be accessed through the Fingenious services (https://site.fingenious.fi/en/) managed by Finnish biobank cooperative. Novel physical activity questions developed in the project as well as their REDCap implementation are available from the corresponding authors upon a reasonable request. The HDI questionnaire is available and administered by the Finnish Institute for Health and Welfare (THL). Developed feedback based on the HDI can be obtained upon a reasonable request from the FOODNUTRI project (KA).
